Search Prime Grants

U01CA258512

Cooperative Agreement

Overview

Grant Description
Protean-CR: Proteomics Toolkit for Ensemble Analysis in Cancer Research - Project Summary

Understanding protein-ligand molecular interactions is fundamental to understanding the role of proteins in complex diseases such as cancer. For instance, there is growing interest in predicting the binding modes of peptide-based ligands (e.g., cyclic and phosphorylated peptides) to inhibit or induce targeted degradation of high-profile cancer targets. Another promising example is the identification of tumor-associated antigens for cancer immunotherapy applications. Both examples involve very specific molecular interactions, provide opportunities for computer-aided design of better cancer treatments, and highlight the need for structural analyses in cancer research. They also require new methods that account for the flexibility and variability of the protein receptors involved in these molecular interactions.

The objective of this project is to develop an integrated approach to the structural modeling and analysis of protein-ligand interactions in cancer research that will be implemented in the proteomics toolkit Protean-CR. The proposed toolkit will adopt a data-science approach to the problem by introducing approaches for data acquisition and aggregation, as well as algorithmic advances for handling receptor flexibility and for modeling driver mutations, drug-resistance polymorphisms, and post-translational modifications. Protean-CR will streamline running structural analyses at scale while providing meaningful data analytics.

The long-term goal of our research is to fully integrate three-dimensional structural information about proteins and ligands and structural analysis into cancer research. The PIs will work with collaborators to target a wide range of users, from experimentalists with little to no programming experience, to advanced users who are comfortable scripting large-scale analyses and integrating the toolkit with their own computational pipeline.

The central hypothesis is that a unified data-science-inspired approach can be used to address major challenges in structural analysis of protein-ligand interactions in cancer research at scale. The first aim will incorporate protein flexibility in docking studies for cancer research. Specific workflows will be used to generate ensembles of protein conformations (receptor flexibility), and innovative machine learning methods will be implemented aiming at a better scoring of protein-ligand complexes. The second aim will focus on including cancer variability into structural analysis. We aim to fill the gap that exists between available data on cancer variants and the structural analysis of ensembles of tumor-associated mutations and protein modifications. Finally, the third aim will focus on customization, interpretability, and scalability, where user-friendly methods will be deployed to manage ensembles of protein-ligand complexes.

Protean-CR will be developed focusing on specific cancer-related projects, and with a broad network of collaborators, enabling the design, implementation, and evolution of the tool according to the needs of the cancer research community.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Place of Performance
Texas United States
Geographic Scope
State-Wide
Analysis Notes
Amendment Since initial award the End Date has been extended from 04/30/24 to 04/30/25 and the total obligations have increased 194% from $402,077 to $1,183,117.
William Marsh Rice University was awarded PROTEAN-CR: Proteomics Toolkit for Ensemble Analysis in Cancer Research Cooperative Agreement U01CA258512 worth $1,183,117 from National Cancer Institute in May 2021 with work to be completed primarily in Texas United States. The grant has a duration of 4 years and was awarded through assistance program 93.396 Cancer Biology Research. The Cooperative Agreement was awarded through grant opportunity Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional).

Status
(Complete)

Last Modified 2/20/24

Period of Performance
5/1/21
Start Date
4/30/25
End Date
100% Complete

Funding Split
$1.2M
Federal Obligation
$0.0
Non-Federal Obligation
$1.2M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to U01CA258512

Subgrant Awards

Disclosed subgrants for U01CA258512

Transaction History

Modifications to U01CA258512

Additional Detail

Award ID FAIN
U01CA258512
SAI Number
U01CA258512-1195492333
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Funding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Awardee UEI
K51LECU1G8N3
Awardee CAGE
0K379
Performance District
TX-90
Senators
John Cornyn
Ted Cruz

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) Health research and training Grants, subsidies, and contributions (41.0) $781,040 100%
Modified: 2/20/24